期刊文献+

小剂量螺内酯对慢性心力衰竭患者心功能及血浆脑钠素的影响 被引量:24

下载PDF
导出
摘要 目的观察小剂量螺内酯对慢性心力衰竭患者心功能及血清脑利钠肽水平的影响。方法选择慢性心力衰竭患者(NYHA心功能分级为Ⅱ级~Ⅲ级)60例,在常规接受洋地黄、利尿剂、血管紧张素转换酶抑制剂类药物治疗基础上,随机分为3组。小剂量螺内酯组20例,在常规治疗基础上每日给予螺内酯20 mg;中剂量螺内酯组20例,在常规治疗基础上每日给予螺内酯40mg。常规治疗组20例,不给予螺内酯治疗,余治疗同前。动态观察心衰患者治疗前及治疗后4个月NYHA分级变化和采用放射免疫法测定血浆脑钠肽(BNP)浓度,并应用心脏彩超测定左室射血分数和左心室舒张末期内径。结果中剂量螺内酯组、小剂量螺内酯组和常规治疗组1个月临床综合疗效分别为90.0%、90.0%和75.0%。螺内脂组与常规组患者治疗4个月后NYHA分级均有所改善,但螺内酯组治疗后改善显著(P〈0.05),治疗后小剂量、中剂量螺内酯组患者左室射血分数显著升高(P〈0.05),治疗后常规治疗组、小剂量、中剂量螺内酯组血清BNP水平显著下降(P〈0.05)。结论小剂量螺内酯能明显改善慢性心力衰竭患者的左室重构及心功能,降低血清脑利钠肽水平。血清脑利钠肽水平可作为评价螺内酯治疗慢性心力衰竭患者疗效评估的指标。
作者 马京炬
出处 《中西医结合心脑血管病杂志》 2011年第3期285-286,共2页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
  • 相关文献

参考文献8

  • 1Zannad F, AIla F, Dousser B, et al. For RALES Investigators. Limita tion of extracelleular matrix turnover may contribute to survival benefit of spironolaetone therapy in patients with congestive heart failure[J].Circulation, 2000,102 : 2700 - 2706.
  • 2Rocha R,Williams GH. Rationale for the use of aldosterone antag- onists in congestive heart failure[J].Drugs, 2002 (62) : 723 - 731.
  • 3Pitt B, Zannad F, Remme WJ,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure[J]. N Engl J Med,1999(34,1) :709 - 717.
  • 4梁茜,李榕生,林爱珍.充血性心力衰竭患者血清Ⅲ型前胶原氨基端肽检测的临床价值[J].中国医师杂志,2002,4(6):641-642. 被引量:3
  • 5Maisel AS, Krishnaswamy P, Nowak RM,et al. Rapid measure of B- type natriuretic poptied in the emergency diagnosis of heart failure[J]. N Engl J Med,2002,347(3) :161 - 167.
  • 6陈协兴,洪华山,王一波,江琼,董现锋,陈良龙.慢性心力衰竭患者血清脑利钠肽水平的变化及其临床意义[J].中国临床药理学与治疗学,2003,8(6):631-634. 被引量:12
  • 7陈协兴,洪华山,王一波,江琼,陈良龙.脑钠素在慢性心力衰竭诊断、预后评估中的价值[J].中国循环杂志,2003,18(6):434-436. 被引量:17
  • 8Macdonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function , vascular angiotensin converting enzyme activity,and other prognostic markers in patients with mild heart failure already taking optimal treatment[J]. Heart, 2004,90 : 765 - 770.

二级参考文献11

  • 1邢云利 贾三庆.BNP可作为心衰诊断和预后的新指标[J].中国医学论坛报,2002,28:14-14.
  • 2刘承云.血清Ⅰ、Ⅲ型前胶原端肽浓度在心血管疾病中的意义[J].国外医学(心血管疾病分册),1997,24(4):18-20. 被引量:22
  • 3[1]Maeda K,Tsutamota T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J,1998,135 : 825-832.
  • 4[2]Maisel AS,Krishnaswamy P, Richards M, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med, 2002,347:161-167.
  • 5[3]Mcdonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left ventricular systolic dysfunction. Lancet, 1998,351:9-13.
  • 6[5]Suzuki T, Yamaoki K, Nakajima O, et al. Screening for cardiac dysfunction in asymptomatic patients by measuring B-type natriuretic peptide levels . Jpn Heart J, 2000,41: 205-214.
  • 7[6]Cowie MW.BNP: soon to become a routine measure in the care of patients with heart failure? Heart,2000,83:617-618.
  • 8[7]Harrison A, Morrison LK, Krishnaswamy P, et al. B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med, 2002, 39: 131-138.
  • 9[8]Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriureric peptide in cardiology.J Lab Clin Med, 1999, 134:437-444.
  • 10沈元琼.高血压病患者与正常人血清Ⅲ型前胶原N-末端肽含量对比研究[J].中国现代医学杂志,1998,8(3):24-25. 被引量:10

共引文献24

同被引文献172

引证文献24

二级引证文献142

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部